Protective Effects of Berberine on Nonalcoholic Fatty Liver Disease in db/db Mice via AMPK/SIRT1 Pathway Activation

Abstract

Objective

Berberine (BBR) has emerged as a promising therapeutic agent for nonalcoholic fatty liver disease (NAFLD). This study aims to elucidate the underlying molecular mechanisms.

Methods

In this study, db/db mice were chosen as an animal model for NAFLD. A total of 10 healthy C57BL/6J mice and 30 db/db mice were randomly allocated to one of 4 groups: the normal control (NC) group, the diabetic control (DC) group, the Metformin (MET) therapy group, and the BBR therapy group. The total cholesterol (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in the serum were measured. The glutathione peroxidase (GSH-Px), glutathione (GSH), malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), interleukin (IL)-1β, tumor necrosis factor (TNF)-α and monocyte chemotactic protein 1 (MCP-1) levels in liver tissue were measured. Hematoxylin and eosin (H&E), acid-Schiff (PAS) and TUNEL stanning was performed for histopathological analysis. Western blotting and immunohistochemistry were conducted to detect the expression levels of key proteins in the AMPK/SIRT1 pathway.

Results

BBR could improve lipid metabolism, attenuate hepatic steatosis and alleviate liver injury significantly. The excessive oxidative stress, high levels of inflammation and abnormal apoptosis in db/db mice were reversed after BBR intervention. BBR clearly changed the expression of AMP-activated protein kinase (AMPK)/Sirtuin 1 (SIRT1), and their downstream proteins.

Conclusion

BBR could reverse NAFLD-related liver injury, likely by activating the AMPK/SIRT1 signaling pathway to inhibit oxidative stress, inflammation and apoptosis in hepatic tissue.

References

[1] Younossi ZM. Non-alcoholic fatty liver disease–A global public health perspective. J Hepatol, 2019, 70(3): 531-544

[2] Riazi K, Azhari H, Charette JH, et al.. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861

[3] Pastori D, Sciacqua A, Marcucci R, et al.. Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation. Mayo Clin Proceed, 2020, 95(3): 513-520

[4] Abd El-Wahab EW, Zein El-Abedin RA, Ahmed WM, et al.. Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. Am J Med Sci, 2020, 360(6): 662-677

[5] Guo K, Xu S, Zeng Z. “Liver–gut” axis: A target of traditional Chinese medicine for the treatment of nonalcoholic fatty liver disease. Front Endocrinol, 2022, 13: 1050709

[6] Sun CC, Zhang CY, Duan JX, et al.. PTUPB ameliorates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome activation in mice. Biochem Biophys Res Commun, 2020, 523(4): 1020-1026

[7] Lan Y, Wu S, Wang Y, et al.. Association between blood copper and nonalcoholic fatty liver disease according to sex. Clin Nutr, 2021, 40(4): 2045-2052

[8] Bórquez JC, Díaz-Castro F, Pino-de La Fuente F, et al.. Mitofusin-2 induced by exercise modifies lipid droplet-mitochondria communication, promoting fatty acid oxidation in male mice with NAFLD. Metabolism, 2024, 152: 155765

[9] You Y, Liang W. SIRT1 and SIRT6: The role in aging-related diseases. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(7): 166815

[10] Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol, 2007, 21(8): 1745-1755

[11] Zeng Y, Hua YQ, Wang W, et al.. Modulation of SIRT1-mediated signaling cascades in the liver contributes to the amelioration of nonalcoholic steatohepatitis in high fat fed middle-aged LDL receptor knockout mice by dihydromyricetin. Biochem Pharmacol, 2020, 175: 113927

[12] Mihanfar A, Akbarzadeh M, Ghazizadeh Darband S, et al.. SIRT1: a promising therapeutic target in type 2 diabetes mellitus. Arch Physiol Biochem, 2024, 130(1): 13-28

[13] Shen S, Shen M, Kuang L, et al.. SIRT1/SREBPs-mediated regulation of lipid metabolism. Pharmacol Res, 2024, 199: 107037

[14] Ren R, He Y, Ding D, et al.. Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPα-miRNA-223 axis. Hepatology, 2022, 75(3): 646-660

[15] Zhang BB, Zhou G, Li C. AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome. Cell Metab, 2009, 9(5): 407-416

[16] Liu J, Chen D, Liu P, et al.. Discovery, synthesis, and structure–activity relationships of 20(S)-protopanaxadiol (PPD) derivatives as a novel class of AMPKα2β1γ1 activators. Eur J Med Chem, 2014, 79: 340-349

[17] Cantó C, Gerhart Hines Z, Feige JN, et al.. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature, 2009, 458(7241): 1056-1060

[18] Zhang D, Ding H, Liu C, et al.. Circulating exosome-mediated AMPKα–SIRT1 pathway regulates lipid metabolism disorders in calf hepatocytes. Vet Res, 2024, 169: 105177

[19] Yin X, Liu Z, Wang J. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis. Phytomedicine, 2023, 119: 155005

[20] Zhou NN, Wang T, Lin YX, et al.. Uridine alleviates high-carbohydrate diet-induced metabolic syndromes by activating sirt1/AMPK signaling pathway and promoting glycogen synthesis in Nile tilapia (Oreochromis niloticus). Ani Nutr, 2023, 14: 56-66

[21] Fang K, Wu F, Chen G, et al.. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells. BMC Complem Altern M, 2019, 19(1): 255

[22] Xu A, Wang L, Luo M, et al.. Overexpression of salusin-β downregulates adipoR1 expression to prevent fatty acid oxidation in HepG2 cells. Mol Med Rep, 2024, 29(2): 18

[23] Liou CJ, Wei CH, Chen YL, et al.. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice. Cell Physiol Biochem, 2018, 49(5): 1870-1884

[24] Wang X, Liang F, Dai Z, et al.. Combination of Coptis chinensis polysaccharides and berberine ameliorates ulcerative colitis by regulating gut microbiota and activating AhR/IL-22 pathway. J Ethnopharmacol, 2024, 318: 117050

[25] Di Pierro F, Sultana R, Eusaph AZ, et al.. Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multicentric, open-label clinical trial. Front Pharmacol, 2023, 14: 1269605

[26] Gasmi A, Asghar F, Zafar S, et al.. Berberine: Pharmacological Features in Health, Disease and Aging. Curr Med Chem, 2024, 31(10): 1214-1234

[27] Tang Y, Gao Y, Nie K, et al.. Jiao-tai-wan and its effective component-berberine improve diabetes and depressive disorder through the cAMP/PKA/CREB signaling pathway. J Ethnopharmacol, 2024, 324: 117829

[28] Cai Y, Yang Q, Yu Y, et al.. Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. Front Pharmacol, 2023, 15: 14:1283784

[29] Tang J, Feng Y, Tsao S, et al.. Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol, 2009, 126(1): 5-17

[30] Devarajan N, Nathan J, Mathangi R, et al.. Pharmacotherapeutic values of berberine: A Chinese herbal medicine for the human cancer management. J Biochem Mol Toxic, 2023, 37(3): e23278

[31] Yan HM, Xia MF, Wang Y, et al.. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One, 2015, 10(8): e0134172

[32] Nejati L, Movahedi A, Salari GR, et al.. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. MJIRI, 2022, 36(1): 294-301

[33] Koperska A, Wesolek A, Moszak M, et al.. Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 2022, 14(17): 3459

[34] Dai Y, Zhu W, Zhou J, et al.. The combination of berberine and evodiamine ameliorates high-fat diet-induced nonalcoholic fatty liver disease associated with modulation of gut microbiota in rats. Braz J Med Biol Res, 2022, 55: e12096

[35] Rafiei H, Yeung M, Kowalski S, et al.. Development of a novel human triculture model of nonalcoholic fatty liver disease and identification of berberine as ameliorating steatosis, oxidative stress and fibrosis. Front Pharmacol, 2023, 14: 12343000

[36] Utami AR, Maksum IP, Deawati Y. Berberine and Its Study as an Antidiabetic Compound. Biology, 2023, 12(7): 973

[37] Zhang H, Zhao C, Cao G, et al.. Berberine modulates amyloid-β peptide generation by activating AMP-activated protein kinase. Neuropharmacology, 2017, 125: 408-417

[38] Wang P, Li R, Li Y, et al.. Berberine alleviates nonalcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice. Gastroenterol Rep (Oxf), 2023, 11: goad032

[39] Liu X, Wang K, Zhou J, et al.. Metformin and Berberine suppress glycogenolysis by inhibiting glycogen phosphorylase and stabilizing the molecular structure of glycogen in db/db mice. Carbohydr Polym, 2020, 243: 116435

[40] Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2010, 7(4): 195-203

[41] Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res, 2018, 7(4): 664-680

[42] Pizzino G, Irrera N, Cucinotta M, et al.. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev, 2017, 2017: 8416763

[43] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al.. Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018, 24(7): 908-922

[44] Chen H, Zhou W, Ruan Y, et al.. Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling. Mol Med, 2018, 24(1): 43

[45] Zhang W, Xu JH, Yu T, et al.. Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. Biomed Pharmacother, 2019, 118: 109131

[46] Ciupińska-Kajor M, Hartleb M, Kajor M, et al.. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int, 2013, 7(1): 233-240

[47] Ramalho RM, Cortez-Pinto H, Castro RE, et al.. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol, 2006, 18(1): 21-29

[48] Panasiuk A, Dzieciol J, Panasiuk B, et al.. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in nonalcoholic fatty liver disease. World J Gastroentero, 2006, 12(38): 5

[49] Wu QJ, Zhang TN, Chen HH, et al.. The sirtuin family in health and disease. Signal Transduct Target Ther, 2022, 7(1): 402

[50] Meng D, Zhang F, Yu W, et al.. Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver. Diabet Metab Synd Ob, 2023, 16: 4043-4064

[51] Yin H, Hu M, Liang X, et al.. Deletion of SIRT1 From Hepatocytes in Mice Disrupts Lipin-1 Signaling and Aggravates Alcoholic Fatty Liver. Gastroenterology, 2014, 146(3): 801-811

[52] Keshavjee B, Lambelet V, Coppola H, et al.. Stress-Induced Premature Senescence Related to Oxidative Stress in the Developmental Programming of Nonalcoholic Fatty Liver Disease in a Rat Model of Intrauterine Growth Restriction. Antioxidants (Basel), 2022, 11(9): 1695

[53] Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harb Perspect Biol, 2009, 1(6): a001651

[54] Yeung F, Hoberg JE, Ramsey CS, et al.. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J, 2004, 23(12): 2369-2380

[55] Rada P, Pardo V, Mobasher MA, et al.. SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress. Antioxid Redox Signal, 2017, 28(13): 1187-1208

[56] Xu G, Zhao J, Liu H, et al.. Melatonin Inhibits Apoptosis and Oxidative Stress of Mouse Leydig Cells via a SIRT1-Dependent Mechanism. Molecules, 2019, 24(17): 3084